Physician profile
Patricia Ejoh
NPI 1710453303
$3,473.56
in general payments reported to CMS, 2019-2025
24 companies · $779 in 2025
The $779 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $652 · 2023: $409 · 2024: $1,198 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $412.23 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $370.74 | 2022-2025 | |
| Lundbeck LLC | $287.12 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $283.68 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $262.69 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.69 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $211.98 | 2021-2022 | |
| Corium, LLC | $185.23 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $174.57 | 2021-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $167.82 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $150.41 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $113.65 | 2024-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $111.61 | 2021-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $110.23 | 2022-2025 | Austedo Xr, Austedo Xr |
| Sage Therapeutics, LLC | $69.72 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $67.91 | 2024 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $59.97 | 2023-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $53.86 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $34.16 | 2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $26.45 | 2025 | Invega Sustenna |
| Indivior INC. | $24.10 | 2022 | |
| Axsome Therapeutics, INC. | $18.72 | 2025 | Auvelity |
| Bausch Health US, LLC | $14.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Ejoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.